Edesa Biotech Other Assets Over Time
| EDSA Stock | USD 2.44 0.14 6.09% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Edesa Biotech Performance and Edesa Biotech Correlation. Edesa |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. If investors know Edesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edesa Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (19.78) | Quarterly Revenue Growth (1.00) | Return On Assets (0.72) | Return On Equity (1.29) |
The market value of Edesa Biotech is measured differently than its book value, which is the value of Edesa that is recorded on the company's balance sheet. Investors also form their own opinion of Edesa Biotech's value that differs from its market value or its book value, called intrinsic value, which is Edesa Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edesa Biotech's market value can be influenced by many factors that don't directly affect Edesa Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edesa Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Edesa Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edesa Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Other Assets Analysis
Compare Edesa Biotech and related stocks such as SAB Biotherapeutics, Senti Biosciences, and Cingulate Other Assets Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SABSW | 40.8 M | 40.8 M | 40.8 M | 40.8 M | 40.8 M | 40.8 M | 40.8 M | 40.8 M | 40.8 M | 40.8 M | 40.8 M | 40.8 M | 40.8 M | 36.7 M | 32.6 M |
| SNTI | 497 K | 497 K | 497 K | 497 K | 497 K | 497 K | 497 K | 497 K | 497 K | 497 K | 497 K | 3.4 M | 3.7 M | 1.0 | 0.95 |
| CING | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (178.8 K) | (178.8 K) | (178.8 K) | (160.9 K) | (152.9 K) |
| INDP | 46.4 K | 46.4 K | 46.4 K | 46.4 K | 46.4 K | 46.4 K | 46.4 K | 46.4 K | 46.4 K | 46.4 K | 44.4 K | 0.0 | 0.0 | 0.0 | 0.0 |
| KTTA | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 1.0 | 0.9 | 0.8 |
| QNRX | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 6.8 M | 26.3 M | 15.3 M | 1.0 | 50 K | 50 K | 383.4 K | (72.0) | (68.4) |
| LIXT | 2.3 K | 2.3 K | 2.3 K | 2.3 K | 2.3 K | 2.3 K | 2.3 K | 2.3 K | 2.3 K | (76.9 K) | (76.9 K) | (150.2 K) | (147 K) | (78 K) | (81.9 K) |
| SABS | 35.5 M | 35.5 M | 35.5 M | 35.5 M | 35.5 M | 35.5 M | 35.5 M | 35.5 M | 35.5 M | 35.5 M | 35.5 M | 35.5 M | 467.7 K | 420.9 K | 399.9 K |
| PCSA | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 5.5 K | 5.5 K | 733.6 K | 5.5 K | 0.0 | 0.0 | 1.0 | 0.9 | 0.86 |
| THRD | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.0 | 0.55 |
| ADTX | 119.4 K | 119.4 K | 119.4 K | 119.4 K | 119.4 K | 119.4 K | 119.4 K | 119.4 K | 119.4 K | 119.4 K | 943.4 K | 668.8 K | 405.4 K | 466.2 K | 587.7 K |
| PALI | 15.7 K | 15.7 K | 15.7 K | 15.7 K | 15.7 K | 15.7 K | 15.7 K | 13.8 K | 24 K | 26 K | 157.6 K | 26 K | 26 K | 29.9 K | 48.2 K |
| PSTV | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 2.1 M | 1.9 M | 2.3 M | 2.6 M | 11.7 M | 72 K | 652 K | 16 K | 12 K | 10.8 K | 10.3 K |
| REVB | 1.8 B | 1.8 B | 1.8 B | 1.8 B | 1.8 B | 1.8 B | 1.8 B | 1.8 B | 2.1 B | 2.5 B | (73.5 M) | 48.3 M | 0.0 | 0.0 | 0.0 |
| NTRB | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 9.6 K | 9.6 K | 9.6 K | 9.6 K | 11.1 K | 11.6 K |
| LGVN | 250.9 K | 250.9 K | 250.9 K | 250.9 K | 250.9 K | 250.9 K | 250.9 K | 250.9 K | 250.9 K | 250.9 K | 2.2 K | 2.3 M | 244 K | 280.6 K | 266.6 K |
| RNXT | 4 K | 4 K | 4 K | 4 K | 4 K | 4 K | 4 K | 4 K | 4 K | 4 K | 4 K | (101 K) | (101 K) | (90.9 K) | (86.4 K) |
| VRAX | (54.5 K) | (54.5 K) | (54.5 K) | (54.5 K) | (54.5 K) | (54.5 K) | (54.5 K) | (54.5 K) | (54.5 K) | (54.5 K) | (54.5 K) | (54.5 K) | (54.5 K) | (49 K) | (51.5 K) |
Edesa Biotech and related stocks such as SAB Biotherapeutics, Senti Biosciences, and Cingulate Other Assets description
My Equities
My Current Equities and Potential Positions
| Edesa Biotech | EDSA |
| Classification | Pharmaceutical Products |
| Location | Ontario; Canada |
| Exchange | NASDAQ Exchange |
USD 2.44
Check out Edesa Biotech Performance and Edesa Biotech Correlation. For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Edesa Biotech technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.